Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 3/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31309796 | 1.00 | KMT2A (0.51) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL31310023 | 1.00 | KMT2A (0.51) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL23200433 | 0.99 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL30895588 | 0.99 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL31284330 | 0.99 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL20450592 | 0.99 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL30895429 | 0.99 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL31013228 | 0.99 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL9989977 | 0.99 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL29887767 | 0.99 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079781-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180037581-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL MYERS SQUIBB CO (US) | 2018-02-08 | — | — | US | disclosed |
| US-9822112-B2 | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822144-B2 | Benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170233436-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-17 | — | — | US | disclosed |
| US-20170233392-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-17 | — | — | US | disclosed |
| US-9676775-B2 | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676794-B2 | Benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170073357-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2017-03-16 | — | — | US | disclosed |
| US-20170057959-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2017-03-02 | — | — | US | disclosed |
| US-20170057959-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2017-03-02 | — | — | US | disclosed |
| US-9527871-B2 | Benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526801-B2 | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160199510-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2016-07-14 | — | — | US | disclosed |
| US-20160200742-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2016-07-14 | — | — | US | disclosed |
| US-8129505-B2 | Formed by catalytic polymerization; antibody conjugates | UCB PHARMA S.A. (BE) | 2012-03-06 | — | — | US | disclosed |
| US-7560284-B2 | Fine particles containing rare earth element and fluorescent probe using the same | DAI NIPPON PRINTING CO., LTD. (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20080292520-A1 | FINE PARTICLES CONTAINING RARE EARTH ELEMENT AND FLUORESCENT PROBE USING THE SAME | MATSUURA DAISUKE | 2008-11-27 | — | — | US | disclosed |
| US-20080220005-A1 | Comb Polymers | UCB PHARMA S.A. (BE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200742-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA3, GABRA2 | KMT2A 874/4885EPHX2 1151/4885LMNA 3208/4885 |
| US-20170073357-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA3, GABRA2 | KMT2A 874/4885EPHX2 1151/4885LMNA 3208/4885 |
| US-20160199510-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA2, GABRA3 | KMT2A 934/4885EPHX2 1012/4885LMNA 3286/4885 |
| US-20170233392-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA2, GABRA3 | KMT2A 934/4885EPHX2 1012/4885LMNA 3286/4885 |
| US-20170057959-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA2, GABRA3 | KMT2A 934/4885EPHX2 1012/4885LMNA 3286/4885 |
| US-20180037581-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA2, GABRA3 | KMT2A 934/4885EPHX2 1012/4885LMNA 3286/4885 |
| US-20080220005-A1 | Comb Polymers | C9, F13B, PYM1 | KMT2A 1777/4885EPHX2 315/4885LMNA 1196/4885 |
| US-20170233436-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA3, GABRA2 | KMT2A 874/4885EPHX2 1151/4885LMNA 3208/4885 |
| US-20180079781-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA3, GABRA2 | KMT2A 874/4885EPHX2 1151/4885LMNA 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.